Effect of verapamil on cell cycle transit and c-myc gene expression in normal and malignant murine cells

K. R. Huber, W. F. Schmidt, E Aubrey Thompson, A. M. Forsthoefel, R. W. Neuberg, R. S. Ettinger

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Verapamil, the prototype calcium channel blocker, reversibly inhibits cell proliferation in many normal and tumour cell lines (Schmidt et al., Cancer Res., 48, 3617, 1988). We have found that two closely related cell line - B16 murine melanoma cells and B10.BR normal murine melanocytes growing in culture - behave differently in the presence of verapamil, and we are now utilising these two related cell lines to help elucidate the molecular basis of verapamil's antiproliferative effect. In this study, we studied cell cycle phase distribution and c-myc gene expression in both cell lines in the absence of verapamil, during incubation with verapamil and after the cells were washed free of verapamil. Our studies show that 100 μM verapamil rapidly blocks DNA synthesis in melanocyte but not in B16 cells. Similarly, incubated with verapamil for 6-24 h results in a decreased c-myc signal in melanomas, but a transient increase in c-myc expression in B16 cells. After verapamil is washed from the cells following a 24-h incubation with drug, c-myc expression increases in melanocytes as they begin again to proliferate, but decreases in B16 cells as they begin to die. Our disparate results with these cell lines suggest that c-myc gene expression, regardless of its known involvement in growth control, is not immediate target for verapamil's inhibitory action.

Original languageEnglish (US)
Pages (from-to)714-718
Number of pages5
JournalBritish Journal of Cancer
Volume59
Issue number5
StatePublished - 1989
Externally publishedYes

Fingerprint

myc Genes
Verapamil
Cell Cycle
Gene Expression
Melanocytes
Cell Line
Experimental Melanomas
Calcium Channel Blockers
Tumor Cell Line
Melanoma
Cell Proliferation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Huber, K. R., Schmidt, W. F., Thompson, E. A., Forsthoefel, A. M., Neuberg, R. W., & Ettinger, R. S. (1989). Effect of verapamil on cell cycle transit and c-myc gene expression in normal and malignant murine cells. British Journal of Cancer, 59(5), 714-718.

Effect of verapamil on cell cycle transit and c-myc gene expression in normal and malignant murine cells. / Huber, K. R.; Schmidt, W. F.; Thompson, E Aubrey; Forsthoefel, A. M.; Neuberg, R. W.; Ettinger, R. S.

In: British Journal of Cancer, Vol. 59, No. 5, 1989, p. 714-718.

Research output: Contribution to journalArticle

Huber, KR, Schmidt, WF, Thompson, EA, Forsthoefel, AM, Neuberg, RW & Ettinger, RS 1989, 'Effect of verapamil on cell cycle transit and c-myc gene expression in normal and malignant murine cells', British Journal of Cancer, vol. 59, no. 5, pp. 714-718.
Huber, K. R. ; Schmidt, W. F. ; Thompson, E Aubrey ; Forsthoefel, A. M. ; Neuberg, R. W. ; Ettinger, R. S. / Effect of verapamil on cell cycle transit and c-myc gene expression in normal and malignant murine cells. In: British Journal of Cancer. 1989 ; Vol. 59, No. 5. pp. 714-718.
@article{c74479a495884e47ab89dafbbc525052,
title = "Effect of verapamil on cell cycle transit and c-myc gene expression in normal and malignant murine cells",
abstract = "Verapamil, the prototype calcium channel blocker, reversibly inhibits cell proliferation in many normal and tumour cell lines (Schmidt et al., Cancer Res., 48, 3617, 1988). We have found that two closely related cell line - B16 murine melanoma cells and B10.BR normal murine melanocytes growing in culture - behave differently in the presence of verapamil, and we are now utilising these two related cell lines to help elucidate the molecular basis of verapamil's antiproliferative effect. In this study, we studied cell cycle phase distribution and c-myc gene expression in both cell lines in the absence of verapamil, during incubation with verapamil and after the cells were washed free of verapamil. Our studies show that 100 μM verapamil rapidly blocks DNA synthesis in melanocyte but not in B16 cells. Similarly, incubated with verapamil for 6-24 h results in a decreased c-myc signal in melanomas, but a transient increase in c-myc expression in B16 cells. After verapamil is washed from the cells following a 24-h incubation with drug, c-myc expression increases in melanocytes as they begin again to proliferate, but decreases in B16 cells as they begin to die. Our disparate results with these cell lines suggest that c-myc gene expression, regardless of its known involvement in growth control, is not immediate target for verapamil's inhibitory action.",
author = "Huber, {K. R.} and Schmidt, {W. F.} and Thompson, {E Aubrey} and Forsthoefel, {A. M.} and Neuberg, {R. W.} and Ettinger, {R. S.}",
year = "1989",
language = "English (US)",
volume = "59",
pages = "714--718",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Effect of verapamil on cell cycle transit and c-myc gene expression in normal and malignant murine cells

AU - Huber, K. R.

AU - Schmidt, W. F.

AU - Thompson, E Aubrey

AU - Forsthoefel, A. M.

AU - Neuberg, R. W.

AU - Ettinger, R. S.

PY - 1989

Y1 - 1989

N2 - Verapamil, the prototype calcium channel blocker, reversibly inhibits cell proliferation in many normal and tumour cell lines (Schmidt et al., Cancer Res., 48, 3617, 1988). We have found that two closely related cell line - B16 murine melanoma cells and B10.BR normal murine melanocytes growing in culture - behave differently in the presence of verapamil, and we are now utilising these two related cell lines to help elucidate the molecular basis of verapamil's antiproliferative effect. In this study, we studied cell cycle phase distribution and c-myc gene expression in both cell lines in the absence of verapamil, during incubation with verapamil and after the cells were washed free of verapamil. Our studies show that 100 μM verapamil rapidly blocks DNA synthesis in melanocyte but not in B16 cells. Similarly, incubated with verapamil for 6-24 h results in a decreased c-myc signal in melanomas, but a transient increase in c-myc expression in B16 cells. After verapamil is washed from the cells following a 24-h incubation with drug, c-myc expression increases in melanocytes as they begin again to proliferate, but decreases in B16 cells as they begin to die. Our disparate results with these cell lines suggest that c-myc gene expression, regardless of its known involvement in growth control, is not immediate target for verapamil's inhibitory action.

AB - Verapamil, the prototype calcium channel blocker, reversibly inhibits cell proliferation in many normal and tumour cell lines (Schmidt et al., Cancer Res., 48, 3617, 1988). We have found that two closely related cell line - B16 murine melanoma cells and B10.BR normal murine melanocytes growing in culture - behave differently in the presence of verapamil, and we are now utilising these two related cell lines to help elucidate the molecular basis of verapamil's antiproliferative effect. In this study, we studied cell cycle phase distribution and c-myc gene expression in both cell lines in the absence of verapamil, during incubation with verapamil and after the cells were washed free of verapamil. Our studies show that 100 μM verapamil rapidly blocks DNA synthesis in melanocyte but not in B16 cells. Similarly, incubated with verapamil for 6-24 h results in a decreased c-myc signal in melanomas, but a transient increase in c-myc expression in B16 cells. After verapamil is washed from the cells following a 24-h incubation with drug, c-myc expression increases in melanocytes as they begin again to proliferate, but decreases in B16 cells as they begin to die. Our disparate results with these cell lines suggest that c-myc gene expression, regardless of its known involvement in growth control, is not immediate target for verapamil's inhibitory action.

UR - http://www.scopus.com/inward/record.url?scp=0024321465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024321465&partnerID=8YFLogxK

M3 - Article

C2 - 2736205

AN - SCOPUS:0024321465

VL - 59

SP - 714

EP - 718

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 5

ER -